Regencell Bioscience Holdings has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Regencell Bioscience Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Regencell Bioscience Holdings's Current Ratio or its related term are showing as below:
During the past 7 years, Regencell Bioscience Holdings's highest Current Ratio was 41.82. The lowest was 0.02. And the median was 3.75.
RGC's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2 * Ranked among companies with meaningful Current Ratio only.
Regencell Bioscience Holdings (NAS:RGC) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Regencell Bioscience Holdings Current Ratio Related Terms
Regencell Bioscience Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regencell Bioscience Holdings (RGC) has a Current Ratio of 0.00 as of Dec. 2025. Over the past decade, Regencell Bioscience Holdings' Current Ratio has ranged from 0.02 to 41.82. According to the industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 998 companies in the Drug Manufacturers industry.
Is Regencell Bioscience Holdings' Current Ratio too high?
Regencell Bioscience Holdings' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 41.82. Based on the distribution chart, Regencell Bioscience Holdings ranks #999999 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Current Ratio compare to ELAN and NBIX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 998 companies for Current Ratio. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median Current Ratio is 2.00. Historically, Regencell Bioscience Holdings' own Current Ratio has ranged from 0.02 to 41.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Regencell Bioscience Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Current Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
33GF Score
Get the complete analysis for RGC
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
